Adalimumab in refractory pediatric tubulointerstitial nephritis and uveitis syndrome: a case report of sustained renal-ocular remission and literature review
Adalimumab can effectively control inflammatory responses and reduce recurrence in pediatric TINU syndrome, with a favorable safety profile, thereby providing a novel and promising biologic alternative for steroid-resistant or refractory cases. It is recommended to focus on ocular lesions in patients with tubulointerstitial injuries to avoid missing the diagnosis of TINU syndrome.
Authors
- Jianjiang Zhang (ORCID: https://orcid.org/0000-0003-2953-1924)
- Weiqin Liu (ORCID: https://orcid.org/0000-0002-9061-3665)
- Xi Wang (ORCID: https://orcid.org/0000-0003-3910-9575)
- Danni Yang (ORCID: https://orcid.org/0009-0009-9259-6967)
- Wai W. Cheung
Institutions
- University of California San Diego (US)
- Rady Children's Hospital-San Diego (US)
- First Affiliated Hospital of Zhengzhou University (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1186/s12882-025-04535-z
- Citations
- 1
- Primary Topic
- Nephrotoxicity and Medicinal Plants
- Type
- article
- Field-Weighted Citation Impact
- 1.36